Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Umea – page 12

178 clinical trials in Umea, Sweden across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Umea at a glance
178
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

178 trials in Umea

Open in trial search

Gastrointestinal stromal tumour

Not recruiting

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:(2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Cholangitis sclerosing

Not recruiting

Study on Simvastatin for Treating Primary Sclerosing Cholangitis in Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Simvastatin
  • Sponsor:Karolinska University Hospital

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Inhaled Imatinib (AV-101) for Patients with Pulmonary Arterial Hypertension (PAH)

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Study on Prednisolone Transfer into Breast Milk and Infant Plasma for Mothers with Rheumatoid Arthritis and Other Inflammatory Conditions

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Betamethasone Sodium Phosphate
  • Sponsor:Uppsala Universitet

Pulmonary arterial hypertension

Not recruiting

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:ABC-15A-116
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Adding Hydroxycarbamide to Standard Treatment with Cytarabine and Daunorubicin for Adults with Newly Diagnosed Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Umea

What the registry says about research in the country

01 Neurodegenerative Diseases

Multiple clinical trials focusing on Amyotrophic Lateral Sclerosis (ALS), including studies of novel treatments like ION363, VHB937, and AMT-162. Research also explores therapeutic approaches for patients with specific genetic mutations.

  • ALS treatment evaluation
  • Genetic mutation therapies
  • Survival and function studies

Additional research includes investigations into ATTR amyloidosis with innovative treatments like vutrisiran and acoramidis.

02 Oncology Research

Comprehensive studies in hematologic malignancies and solid tumors, including trials for chronic lymphocytic leukemia, follicular lymphoma, and breast cancer. Research in Stockholm examines innovative treatment approaches for various cancer types.

  • Leukemia and lymphoma treatments
  • Breast cancer endocrine therapy
  • Prostate cancer management

Notable focus on biomarker-guided treatments and targeted therapies for better patient outcomes.

03 Preventive Medicine

Studies examining preventive approaches including HPV vaccination and screening programs. Research includes novel dengue fever vaccine trials and investigations into colorectal cancer prevention in Lynch syndrome patients.

  • Vaccine effectiveness studies
  • Cancer prevention strategies
  • Screening program optimization

Focus on population-level interventions and long-term disease prevention strategies.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.